PMID- 32269970
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2287-979X (Print)
IS  - 2288-0011 (Electronic)
IS  - 2287-979X (Linking)
VI  - 55
IP  - 1
DP  - 2020 Mar
TI  - A general view of CD33(+) leukemic stem cells and CAR-T cells as interesting 
      targets in acute myeloblatsic leukemia therapy.
PG  - 10-16
LID - 10.5045/br.2020.55.1.10 [doi]
AB  - Acute myeloblastic leukemia (AML) is the most frequent acute leukemia in 
      adulthood with very poor overall survival rates. In the past few decades, 
      significant progresses had led to the findings of new therapeutic approaches and 
      the better understanding of the molecular complexity of this hematologic 
      malignancy. Leukemic stem cells (LSCs) play a key role in the initiation, 
      progression, regression, and drug resistance of different types of leukemia. The 
      cellular and molecular characteristics of LSCs and their mechanism in the 
      development of leukemia had not yet been specified. Therefore, determining their 
      cellular and molecular characteristics and creating new approaches for targeted 
      therapy of LSCs is crucial for the future of leukemia research. For this reason, 
      the recognition of surface maker targets on the cell surface of LSCs has 
      attracted much attention. CD33 has been detected on blasts in most AML patients, 
      making them an interesting target for AML therapy. Genetic engineering of T cells 
      with chimeric antigen receptor (CAR-T cell therapy) is a novel therapeutic 
      strategy. It extends the range of antigens available for use in adoptive T-cell 
      immunotherapy. This review will focus on CAR-T cell approaches as well as 
      monoclonal antibody (mAB)-based therapy, the two antibody-based therapies 
      utilized in AML treatment.
CI  - (c) 2020 Korean Society of Hematology.
FAU - Fathi, Ezzatollah
AU  - Fathi E
AD  - Department of Clinical Sciences, Faculty of Veterinary Medicine, University of 
      Tabriz, Tabriz, Iran.
FAU - Farahzadi, Raheleh
AU  - Farahzadi R
AD  - Hematology and Oncology Research Center, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
FAU - Sheervalilou, Roghayeh
AU  - Sheervalilou R
AD  - Cellular and Molecular Research Center, Zahedan University of Medical Sciences, 
      Zahedan, Iran.
FAU - Sanaat, Zohreh
AU  - Sanaat Z
AD  - Hematology and Oncology Research Center, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
FAU - Vietor, Ilja
AU  - Vietor I
AD  - Division of Cell Biology, Biocenter, Medical University Innsbruck, Innsbruck, 
      Austria.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200330
PL  - Switzerland
TA  - Blood Res
JT  - Blood research
JID - 101605247
PMC - PMC7106116
OTO - NOTNLM
OT  - Acute myeloblastic leukemia
OT  - CAR-T cell
OT  - CAR-T cell immunotherapy
OT  - CD33+ leukemic stem cells
OT  - Cancer stem cells
OT  - mAB-based therapy
COIS- Authors' Disclosures of Potential Conflicts of Interest: No potential conflicts 
      of interest relevant to this article were reported.
EDAT- 2020/04/10 06:00
MHDA- 2020/04/10 06:01
PMCR- 2020/03/01
CRDT- 2020/04/10 06:00
PHST- 2020/02/12 00:00 [received]
PHST- 2020/02/27 00:00 [revised]
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/04/10 06:00 [entrez]
PHST- 2020/04/10 06:00 [pubmed]
PHST- 2020/04/10 06:01 [medline]
PHST- 2020/03/01 00:00 [pmc-release]
AID - 10.5045/br.2020.55.1.10 [doi]
PST - ppublish
SO  - Blood Res. 2020 Mar;55(1):10-16. doi: 10.5045/br.2020.55.1.10. Epub 2020 Mar 30.